Niki BioSolutions (NIKI) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pluri (PLUR) has outperformed Niki BioSolutions (NIKI) over the past year, losing 75.5% versus a loss of 82.1%. Over five years, PLUR leads with a -95.2% price change compared with -98.3% for NIKI. Niki BioSolutions is the larger company by market cap ($13.5 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NIKI | PLUR |
|---|---|---|
| Share price | $4.32 | $1.00 |
| Market cap | $13.47M | $12.61M |
| 1-day change | -7.10% | -3.85% |
| YTD return | -59.25% | -66.56% |
| 1-year return | -82.07% | -75.49% |
| 5-year return | -98.33% | -95.23% |
| EPS (TTM) | $-2.90 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.00 | $4.87 |
| 52-week low | $4.10 | $0.85 |
| Distance from 52-week high | -82.00% | -79.47% |
| Average volume | 157.52K | 24.97K |
| Shares outstanding | 2.94M | 12.61M |
| Employees | 1 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Healthcare · Biotechnology · 1 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
NIKI vs PLUR FAQ
Which is bigger, Niki BioSolutions or Pluri?
Niki BioSolutions (NIKI) is larger, with a market capitalization of $13.47M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, NIKI or PLUR?
PLUR returned -75.49% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are Niki BioSolutions and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.